European Lung Cancer Working Party Clinical Practice Guidelines. Small Cell Lung Cnacer: IV. Limited disease

The present guidelines on the management of limited disease small cell lung cancer (SCLC) were formulated by the ELCWP in April 2007. They are designed to answer the following seven questions: 1) What is the definition of limited disease? 2) Should chest radiotherapy be provided and what are the benefits? 3) What is the optimal timing and mode of administration of chest irradiation? 4) Which are the optimal radiotherapy parameters: dose, fractionation, target volume? 5) What is the optimal chemotherapy regimen for limited disease SCLC? 6) Should prophylactic cranial irradiation be provided, when and for which patients? 7) What is the additional role of thoracic surgery in early SCLC

Monoclonal immunoradiometric assay and polyclonal radioimmunoassay compared for measuring neuron-specific enolase in patients with lung cancer

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma

Few chemotherapeutic agents have demonstrated their efficacy in malignant mesothelioma. The cisplatin plus doxorubicin combination has one of the highest response rates. Epirubicin is an anthracyclin, analogous to doxorubicin, with a different toxicologic pattern. As there are no data on the activity of the combination cisplatin plus epirubicin in malignant mesothelioma, the European Lung Cancer Working Party (ELCWP) designed a phase II study with response rate as primary objective. Sixty-nine eligible patients with malignant pleural mesothelioma were centrally registered. The majority of the patients were male (n = 59), had a Karnofsky performance status of 80 or more (n = 62) and presented with an epithelial histologic subtype (n = 43). Median age was 62 years. In nine patients, metastases were documented at the initial work-up, mainly in bone, lung and skin. Three hundred and twenty-four cycles of chemotherapy were administered. The main toxicities were nausea and vomiting, neutropenia and alopecia. Among 63 assessable patients, response rate was 19.0% (95% confidence interval [CI] 9-29%). Median survival was 13.3 months. In multivariate analysis, poor prognostic factors for survival were neutrophil count and CALGB groups 4-6. In conclusion, cisplatin plus epirubicin appears as an effective regimen in malignant mesothelioma, with a favourable toxicity profile. However, it does not demonstrate superior activity to other active regimens in this disease. © 2005 Elsevier Ireland Ltd. All rights reserved.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Resectability after two different chemotherapy regimens: results of the first step of a phase II randomised trial in initially resectable stage I-IIIa non-small cell lung cancer conducted by the European Lung Cancer Working Party

10th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Vancouver, Canada, 10-14/08/2003info:eu-repo/semantics/publishedsuppl 2

A phase II study testing weekly platinum derivative combination chemotherapy as second-line treatment in patients with advanced small cell lung cancer

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

A phase II study testing a combination chemotherapy with epirubicin and vindesine as second line treatment for patients with advanced non-small cell lung cancer

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Phase II randomized trial comparing high-dose cisplatin with moderate- dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Final results of a trial comparing two neoadjuvant chemotherapy (CT) regimens followed by surgery in patients with resectable non-small cell lung cancer (NSCLC): A phase II randomized study by the European lung cancer Working Party

Proceedings ASCO :P7055 mai 2011.info:eu-repo/semantics/publishe

Induction chemotherapy with ifosfamide, etoposide, and anthracycline for small cell lung cancer: Experience of the European Lung Cancer Working Party

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

How much can patients with low Karnofsky performance status and advanced non-small cell lung cancer, benefit from cisplatin-based chemotherapy? A retrospective analysis of a phase III randomised trial

43rd ASCO Annual Meeting, Chicago, USAinfo:eu-repo/semantics/publishe